Navigation Links
Alfacell Provides ONCONASE(R) NDA Submission Update
Date:1/27/2009

SOMERSET, N.J., Jan. 27 /PRNewswire-FirstCall/ -- Alfacell Corporation (OTC Bulletin Board: ACEL) today reported that it has conducted a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) to discuss the company's planned submission of the final components of the ONCONASE rolling New Drug Application (NDA) for the treatment of unresectable malignant mesothelioma (UMM) patients. At the pre-NDA meeting, the FDA provided guidance to the company recommending that an additional clinical trial be conducted in UMM patients that have failed one prior chemotherapy regimen, prior to submitting a NDA.

As the company has previously reported, the results of the preliminary statistical analysis of the data from the confirmatory Phase IIIb clinical trial for ONCONASE in patients suffering from UMM did not meet statistical significance for the primary endpoint of survival in UMM. However, a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen, a pre-defined primary data set for this sub-group of patients in the trial, which represents a currently unmet medical need.

The company's current financial situation does not allow it to pursue additional clinical trials until other sources of capital are secured. The company will effect a reduction in force on January 30, 2009 and otherwise reduce its operations to the minimum sustainable level required to pursue strategic alternatives and additional capital. Based upon these actions the company expects that its current cash reserves will enable it to maintain its reduced operations through December 2009. The company intends to continue to explore strategic alternatives and additional capital. Additionally, the company's board of directors has agreed to forgo cash compensation effective as of January 1, 2009.

About ONCONASE(R)

ONCONASE is a first-in-class therapeuti
'/>"/>

SOURCE Alfacell Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Alfacells ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells
2. Alfacell Receives Going Concern Audit Opinion
3. Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
4. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
5. Alfacell Hires Advisors to Advance Strategic Alternatives
6. Alfacell Receives NASDAQ Delisting Letter
7. Alfacell Receives NASDAQ Non-Compliance Notification
8. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
9. Alfacell Announces Retirement of Chief Executive Officer
10. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
11. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... (PRWEB) April 23, 2015 ... refer to a series of genetic tests that ... fibrosis, Lou Gehrig's disease, Huntington's disease, and Alzheimer's ... the gene composition and interaction in diseased tissue/cells ... as well as the response to treatment, such ...
(Date:4/23/2015)... Proove Biosciences , a ... excited to announce the launch of Proove ... assesses 62 genetic variations to predict good versus ... prescribed non-opioid pain medications, namely ibuprofen (brand name ... name Xanax) and acetaminophen (brand name Tylenol). ...
(Date:4/23/2015)... CA (PRWEB) April 23, 2015 Delpor, ... today announced that the United States Patent and Trademark ... Company’s NANOPOR™ technology. US Pat. No. ... Delpor’s microfabricated drug delivery device for the ... proprietary NANOPOR™ technology for the sustained (zero-order) release of ...
(Date:4/22/2015)... Wilmington, Del. (PRWEB) April 22, 2015 ... acquire Taxon Biosciences, Inc., a leading microbiome discovery ... capabilities and unparalleled market access in both seed ... solutions for agriculture customers globally. , “In ... Health and Industrial Biosciences segments sold more than ...
Breaking Biology Technology:Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3DuPont Acquires Taxon Biosciences, Inc. 2DuPont Acquires Taxon Biosciences, Inc. 3DuPont Acquires Taxon Biosciences, Inc. 4
... TELK ) reported a net loss of $13.6 million, or ... compared with a net loss of,$14.3 million, or $0.27 per ... loss for the second quarter ended June 30, 2008, includes,a ... reflected in interest and other income (expense)., For the ...
... NEW YORK, Aug. 11 Immtech Pharmaceuticals,Inc. (Amex: ... ended June,30, 2008., For the three months ended ... for the three months ended June 30, 2007. The ... testing,agreement. Loss from operations for the three months ended ...
... GSK anticipates delivery of at least half of ... Aug. 11 GlaxoSmithKline (NYSE:,GSK) today announced that ... and FLUARIX(R) [Influenza Virus Vaccine] to U.S. customers,for ... Drug Administration,s,(FDA) Center for Biologics Evaluation and Research ...
Cached Biology Technology:Telik Announces Financial Results For 2008 Second Quarter 2Telik Announces Financial Results For 2008 Second Quarter 3Telik Announces Financial Results For 2008 Second Quarter 4Immtech Reports Fiscal First Quarter 2009 Results 2Immtech Reports Fiscal First Quarter 2009 Results 3GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season 2GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season 3GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season 4
(Date:4/2/2015)... April 2, 2015 Fingerprint Cards ... sensor FPC1025 from the distributor World Peace Industrial Group ... Q2 2015 although the major part of the shipments ... be used by smartphone manufacturers in China ... included in the communicated revenue guidance of + 1 000 ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... Center researchers reveals how a well-known tumor suppressor gene may ... published online today in Oncogene , focus on the ... who have hereditary breast and/or ovarian cancers, according to senior ... of Human Science at the School of Nursing & Health ...
... dementia and while some risks are known, for example ... clear. New research published in BioMed Central,s open access ... hospitalization and treatment in the intensive care unit (ICU) ... such as delirium, or acute dialysis are all independently ...
... small-scale polar storms could make a big difference to climate ... Anglia and the University of Massachusetts. Difficult-to-forecast polar ... are missing in most climate models. Research published ... could paint a different picture of climate change in years ...
Cached Biology News:Study uncovers mechanism used by BRCA1 to suppress tumors 2Worries about dementia how hospitalization affects the elderly 2'Missing' polar weather systems could impact climate predictions 2
... The lyophilization stabilizer is designed to ... and for long-term storage. There ... ingredients. It is a convenient ... 7.2, and is superior to other ...
... The CERTOMAT IS, a true benchtop incubator-shaker, has ... Having a footprint of 540 x 680 ... large incubation chamber (370 x 505 x 510mm). ... the CERTOMAT IS is ideal for shaking applications ...
... TC-3000 is one of the smallest thermal cyclers ... choice of either the 0.5ml (20 samples) or ... , Fast heating and cooling rate of ... and high performance Fast track programming with ...
... StabilZyme HRP Conjugate Stabilizer is an aqueous ... and other non-toxic stabilizing chemicals in a ... 6.7. This product contains a ... 20 ppm Proclin 300 (Rohm and Haas ...
Biology Products: